New Haven, Conn., May 26, 2005 - The Connecticut Senate today passed Senate Bill No. 934, an act permitting embryonic stem cell research. CURE (Connecticut United for Research Excellence, Inc.) was a leading proponent and resource in the research and drafting of the bill. Paul R. Pescatello, president and chief executive officer of CURE, issued the following comment.

"For those suffering from a host of diseases and conditions - such as Lou Gehrig's disease, Parkinson's disease, spinal cord injury and multiple sclerosis - today's action marks a significant step forward.

Besides providing funding for research grants, the bill is also a further step towards attracting substantial investment and high-paying jobs to the State.

We are lucky here in Connecticut to have bipartisan support for this measure. The moment is at hand to establish our state as a center for embryonic stem cell research.

CURE (http://www.curenet.org) is a statewide coalition of over 100 educational and research institutions, biotechnology and pharmaceutical companies and other supporting businesses. It is dedicated to promoting the growth and increasing public understanding of biomedical research and science in Connecticut.

available in pdf here.